Oxford Biomedica's (OXB) "Buy" Rating Reiterated at Jefferies Financial Group

Key Points

• Jefferies reaffirmed a “Buy” rating on Oxford Biomedica and set a GBX 827 price target, implying 58.43% upside from the prior close.
• Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and an average price target of GBX 818; RBC also rates the stock “Outperform,” while Deutsche Bank rates it “Hold.”
• Oxford Biomedica reported a quarterly loss of GBX 30.39 per share and maintains negative profitability metrics, while insider Roch Doliveux purchased 20,250 shares worth approximately £102,263.

Oxford Biomedica (LON:OXB - Get Free Report)'s stock had its "buy" rating reaffirmed by Jefferies Financial Group in a report released on Monday, London Stock Exchange reports. They presently have a GBX 827 target price on the biopharmaceutical company's stock. Jefferies Financial Group's price objective points to a potential upside of 58.43% from the stock's previous close.

OXB has been the topic of a number of other reports. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a GBX 900 price target on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a GBX 595 price objective on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of GBX 818.

Oxford Biomedica Stock Up 1.6%

OXB opened at GBX 522 on Monday. The company has a market cap of £631.87 million, a P/E ratio of -16.33 and a beta of 1.11. The business's 50-day moving average price is GBX 494.55 and its 200-day moving average price is GBX 563.32. The company has a current ratio of 2.21, a quick ratio of 1.67 and a debt-to-equity ratio of 273.08. Oxford Biomedica has a 12 month low of GBX 420 and a 12 month high of GBX 952.

Oxford Biomedica (LON:OXB - Get Free Report) last released its earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. On average, equities analysts expect that Oxford Biomedica will post -31.08 EPS for the current year.

Insider Activity

In other news, insider Roch Doliveux acquired 20,250 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was purchased at an average cost of GBX 505 per share, with a total value of £102,262.50. Insiders own 25.83% of the company's stock.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.